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Recent development in clinical applications
of PD-1 and PD-L1 antibodies for cancer
immunotherapy
Bingshan Liu1,2, Yongping Song2* and Delong Liu2*
Abstract
Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies
against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expanding. Incorporation of PD
antibodies into chemotherapy regimens is in active clinical investigations. The combination of pembrolizumab with
carboplatin and pemetrexed has been approved for the first line therapy of metastatic non-squamous non-small cell
lung cancer. Combination of PD-1/PD-L1 antibodies with small molecule inhibitors such as tyrosine kinase inhibitors
and IDO inhibitors are in active clinical trials. This review summarized recent development in clinical trials of PD-1 and
PD-L1 antibodies for cancer immunotherapy.
Background
Targeted therapies for cancer with small molecules and
monoclonal antibodies (MoAb) have led to significant
improvement in the long-term survival of multiple
malignancies [1–11]. The discovery of programmed death-
1 (PD-1) and the ligand 1 (PD-L1) has opened the door to
the modern era of cancer immunotherapy [12, 13]. It is well
known now that many tumor cells are able to upregulate
the expression of PD-L1 which leads to anergy of cytotoxic
T cells upon PD-1 binding to the ligand. Blocking the PD-1
pathway using monoclonal antibodies against PD-1 or PD-
L1 can therefore revamp the immune response against
tumor cells [14]. The development of MoAbs against PD-1
and PD-L1 has led to the fast and fundamental paradigm
shift in cancer therapy [15]. The anti-PD drugs are the new
form of tumor-site immune modulation therapy through
resetting immune reservoir in the tumor microenvironment
[16, 17]. This is fundamentally different from the conven-
tional chemotherapy and radiation that mainly target
cancer cells themselves.
PD-L1 expression on the tumor cells and immune
cells have become biomarkers that can assist clinical
decisions in the choice of treatment strategies [18, 19].
Biomarker assays for PD-L1 are playing bigger roles and
are being routinely done nowadays. However, PD-L1
assays can be highly variable, which makes it a clinical
challenge to employ the results. In this review, we
summarized latest clinical development of PD antibodies
and immunohistochemistry (IHC) assays for PD-L1 bio-
marker expression in clinical practice.
New development in clinical applications of PD-1
and PD-L1 antibodies
The US Food and Drug Administration (FDA) has
approved 5 immune checkpoint blockers in 11 types of
advanced malignancies (Table 1).
Nivolumab has FDA approved indications for treat-
ment of eight types of advanced malignancies. These
malignancies include melanoma, NSCLC (non-small cell
lung cancer), classical Hodgkin lymphoma, HNSCC
(squamous cell carcinoma of the head and neck), renal
cell carcinoma, urothelial carcinoma, hepatocellular
carcinoma, and microsatellite instability (MSI)-high or
mismatch repair gene (MMR)-deficient colorectal cancer
(Table 1) [20–35]. It has been observed that pneumonitis
may be associated with responses to PD antibodies [36, 37].
Nivolumab is being explored in more and more cancer
types. Twenty patients with platinum-resistant ovarian
cancer were treated with nivolumab in a phase II trial.
Patients received up to six cycles (four doses per cycle).
Twenty nivolumab-treated patients were evaluable at the
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time of the report and found to have ORR of 15%. Two
of the responding patients had a durable CR (in the
3 mg/kg cohort). At the termination of the study, the
median PFS was 3.5 months and the median overall sur-
vival (OS) was 20.0 months. The encouraging results
from this pilot study of nivolumab in patients with
platinum-resistant ovarian cancer suggest potential
benefit of PD-1 antibody for refractory ovarian cancer
[38]. Nivolumab is being studied in a phase I trial as a
maintenance therapy for patients with high-risk
hematological malignancies (NCT02985554). More than
350 trials of nivolumab have been registered on
clinicaltrials.gov.
Currently, pembrolizumab has FDA approved indica-
tions of seven different types of advanced malignancies.
These malignancies include melanoma [39, 40], NSCLC
[41–44], HNSCC, urothelial carcinoma, Hodgkin’s lymph-
oma [45], and gastric cancer [46, 47] (Table 1). Among
these, FDA approved one indication for any malignancy
with high microsatellite instability or mismatch repair
gene (MMR) deficiency [48]. However, response to pem-
brolizumab in a gastric patient with stable MSI and profi-
cient MMR has been observed [49]. Pembrolizumab has
also been reported to be active in other highly refractory
malignancies, such as Ewing’s sarcoma [50]. Recently,
pembrolizumab was reported to be active in patients with
refractory large cell lymphoma of the mediastinum [51].
Pembrolizumab has been studied in 26 patients with
advanced Merkel cell carcinoma who had not received
previous systemic therapy [52]. The overall response rate
was 56%. The responses were seen in tumors with posi-
tive Merkel cell polyomavirus as well as in those with
negative viral infections.
Atezolizumab is approved for treatment of advanced
NSCLC and urothelial carcinoma [53–61]. The clinical
activity of atezolizumab (MPDL3280A) in renal cell car-
cinoma (RCC) has been evaluated in 70 patients with
metastatic RCC [62]. There were 63 with clear cell RCC
and 7 with non-clear cell histology. These patients
received atezolizumab every 3 weeks. PD-L1 expression
was assessed with the Ventana SP142 assay on tumor
cells and tumor-infiltrating immune cells (IC). For
patients with clear cell RCC, the OS was 28.9 months
(95% CI, 20.0 months to not reach) and PFS was
5.6 months (95% CI, 3.9 to 8.2 months). The ORR was
15% (95% CI, 7 to 26%). When the response was corre-
lated with PD-L1 expression on IC cells, it was found
that higher response rate was seen in PD-L1 expression ICs
(18% RR in IC1/2/3, 9% RR in IC0). This study provided
data to guide further trials with atezolizumab in RCC.
Durvalumab is approved for treatment of advanced
urothelial carcinoma [63, 64]. Recently, the result of
PACIFIC study was reported [65]. This was a random-
ized, placebo-controlled study of consolidation therapy
for non-resectable stage III NSCLC after 2 cycles of
planned chemoradiotherapy. Durvalumab was given as
10 mg/kg iv infusion over 30 min every 2 weeks up to
12 months. The PFS was significantly better for durvalu-
mab (16.8 months, 95% CI 13 to 18.1 m) than that of
the placebo arm (5.6 m, 95% CI, 4.6–7.8 m), p < 0.001).
Overall survival as the secondary endpoint favored dur-
valumab, whereas the safety measures were similar in
both groups. From this study, durvalumab was found to
prolong PFS for approximately 11 months.
Avelumab is approved for treatment of advanced
Merkel cell cancer and advanced urothelial carcinoma
[66, 67]. In a dose-escalation phase 1a trial, avelumab
has demonstrated an acceptable safety profile and early
suggestion of activity in patients with advanced solid
tumors [68]. A phase Ib dose-expansion cohort of that
trial was done in a cohort of patients with advanced,
platinum-treated non-small-cell lung cancer (NSCLC)
[69]. In this trial, 184 patients were treated with avelu-
mab and followed for a median of 8.8 months. Severe
Table 1 Clinical applications of PD-1 and PD-L1 antibodies
Antibodies Dosagesa Indicationsb
Pembrolizumab 200 mg over 60 min q3 weeks Melanoma, NSCLC, HNSCC, urothelial carcinoma, Hodgkin’s lymphoma,
MSI-high cancer, gastric cancer
200 mg over 60 min q3 weeks
carboplatin/pemetrexed
First line combination therapy for metastatic non-squamous NSCLC
Nivolumab 240 mg over 60 min q2 weeks Melanoma, NSCLC, renal cell carcinoma, urothelial carcinoma,
MSI-high /dMMR CRC, HCC
3 mg/kg over 60 min q2 weeks Hodgkin’s lymphoma, HNSCC
Atezolizumab 1200 mg over 60 min q3 weeks Urothelial carcinoma, NSCLC
Durvalumab 10 mg/kg over 60 min q2 weeks Urothelial carcinoma
Avelumab 10 mg/kg over 60 min q2 weeks Merkel cell carcinoma, urothelial carcinoma
Abbreviations: NSCLC non-small cell lung cancer, HNSCC head/neck squamous cell carcinoma, MSI microsatellite instability; dMMR deficient mismatch repair gene,
CRC colorectal cancer, HCC hepatocellular carcinoma, min minute, q3w every 3 weeks
aFfor pediatric dosing and for combination dosage and schedules, please refer to full prescribing information for each individual agent
bFor exact indications, please refer to full prescribing information for each individual agent
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adverse events (SAE) occurred in 44% of the 184
patients. The most common treatment-emerging adverse
events (TEAE) among the 184 patients were fatigue 25%,
infusion-related reaction (IRR) 21%, and nausea 13%.
The ORR was 12% (95% CI 8–18), including 1 CR and 21
PR. In addition, 38% had stable disease. Further study on
avelumab for advanced NSCLC appears to be warranted.
Combination studies of PD-1 and PD-L1 antibodies
with chemotherapy
In an attempt to enhance clinical benefits of cancer
immunotherapy, PD antibodies are being evaluated in
clinical trials in combination with chemotherapeutic
agents [70]. The benefit of PD antibody in combination
with radiation remains to be determined [71].
Nivolumab in combination with ipilimumab has been
shown to improve progression-free survival of and
approved for unresectable or metastatic melanoma [72].
A recent update from this trial revealed benefit on pro-
longed 3-year overall survival [73]. Nivolumab plus ipili-
mumab combination was studied in an open-label,
phase 1, multi-cohort study (CheckMate 012) treatment-
naïve patients with recurrent stage IIIb or stage IV
NSCLC [74]. The first-line nivolumab plus ipilimumab
was tolerable and showed a high response rate. This
study supports further clinical trial of this combination
in a phase 3 study.
Nivolumab plus platinum-based doublet chemotherapy
(PT-DC) was evaluated for safety and tolerability as
first-line therapy in 56 patients with advanced NSCLC
[75]. Nivolumab plus PT-DC were given concurrently
every 3 weeks for 4 cycles. This was followed by nivolu-
mab alone as maintenance until progression or unaccept-
able toxicity. SAEs occurred in 45% of the patients. Seven
percent had pneumonitis. AE-related discontinuation rate
was reported more with the combination. Similar responses
were seen in all dose levels irrelevant of PD-L1 expression.
2-year OS rate reached 62% in the nivolumab 5 mg/kg plus
PT-DC group. This may warrant further investigation.
Pembrolizumab was studied in combination with the
doublet chemotherapy of carboplatin and pemetrexed in
a multicenter randomized phase II study for patients
with chemotherapy-naïve stage IIIB/IV non-squamous
NSCLC and without EGFR or ALK mutations (KEY-
NOTE-021) [76]. In this study, PD-L1 tumor proportion
score was stratified as < 1% vs >/= 1%. A total of 123
patients were enrolled in this published report. Among
these patients, 60 received pembrolizumab plus chemo-
therapy (the combination group) and 63 had chemother-
apy alone. Four cycles of pembrolizumab 200 mg plus
carboplatin area under curve 5 mg/mL per min and
pemetrexed 500 mg/m2 every 3 weeks were given to all
patients. This was followed by pembrolizumab for
24 months and indefinite pemetrexed maintenance
therapy versus indefinite pemetrexed maintenance therapy
alone. At disease progression, those patients in the peme-
trexed alone group were allowed for crossover to receive
pembrolizumab. The primary endpoint was objective
response rate (ORR). The ORR in the combination group
was 55% (95% CI 42–68). This was significantly better
than that in the pemetrexed alone group (29%; 18–41)
(p = 0.0016). The incidence of severe treatment-emerging
adverse events (TEAEs) was similar, and the most com-
mon ones were anemia and neutropenia. This was the first
prospective randomized study that showed a benefit of a
triplet regimen over doublet chemotherapy. This combin-
ation modality has been approved by FDA as the first line
treatment for metastatic non-squamous NSCLC (Table 1).
The benefit of adding pembrolizumab to platinum-
doublet is being confirmed in two ongoing international,
randomized, double-blind, phase 3 studies, KEYNOTE-
189/NCT02578680 and KEYNOTE-407/NCT02775435.
Combination studies of PD-1 and PD-L1 antibodies
with other agents
Bevacizumab was combined with atezolizumab in a trial
for metastatic RCC. When intra-tumoral CD8(+) T cells
were enumerated and compared, it was found that the T
cells increased in number following combination treat-
ment. Biomarkers were examined in the study. Increase
in chemokines was most notable for CX3CL1 (fractalk-
ine) and its receptors. Following bevacizumab and atezo-
lizumab combination treatment, more lymphocytes were
seen in tumor tissues. This study suggests that the
bevacizumab and atezolizumab combination improves
antigen-specific T-cell migration [77].
Durvalumab was studied in a phase Ib trial in combin-
ation with osimertinib in NSCLC patients with EGFR
activating mutations. The part A enrolled patients who
were pretreated with EGFR tyrosine kinase inhibitors
(TKI), and the part B enrolled treatment-naïve NSCLC
patients. This combination was terminated for further
enrollment due to high incidence of interstitial lung
disease (38%) [78]. In a separate study, durvalumab was
evaluated in a phase I trial in combination with gefitinib
in treatment-naïve patients with NSCLC [79]. Early
results appeared to be encouraging yet higher incidence
of grade 3/4 liver enzyme elevation (40–70%) was
observed. Atezolizumab was also studied in a phase I
trial in combination with erlotinib in NSCLC patients
with EGFR activating mutations [80]. In this report, 28
patients were included. TEAEs were seen in 50% of the
patients, though no pneumonitis was reported. Early results
from combination of EGFR TKIs with immunotherapy re-
vealed higher incidence of TEAEs. Therefore, the combin-
ation therapy of EGFR TKI and immunotherapy remains
investigational [78].
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PD-1 antibodies are also being studied in combination
with indoximod, an inhibitor of indoleamine 2,3-dioxi-
genase 1 (IDO1) (NCT03301636) [81]. In a single arm
phase 2 study of indoximod in combination with
immunotherapy for patients with metastatic melanoma,
a large majority of patients received indoximod with pem-
brolizumab as reported in an interim analysis [82]. Indoxi-
mod was given as 1200 mg PO twice daily concurrently
with pembrolizumab (3 mg/kg q 21 days). The primary
endpoint was ORR. In this report, 60 patients received the
indoximod/pembrolizumab combination. The ORR was
52% (CR 8%+ PR 44%). The combination was well toler-
ated. GI toxicities, anemia (17%), and hyperglycemia
(17%) were the most common adverse events. A random-
ized phase 2/3 study of indoximod in combination with
pembrolizumab or nivolumab is ongoing in patients with
advanced melanoma (NLG2107, NCT03301636). Other
IDO inhibitors are also being evaluated in combination
with immunotherapy [81].
Bioassays for PD-L1
The discovery of targetable oncogenes led to the routine
molecular testing for gene mutations, such as those
genes encoding epidermal growth factor receptor
(EGFR) and BRAF V600E, ALK, the rat osteosarcoma
(ROS1), FLT3, and IDH1/2 [41, 83]. More and more
companion or complementary diagnostic assays are being
approved upon approval of pharmaceutical products. A
companion diagnostic assay is defined as a necessary test
for the safe and efficacious use of a corresponding drug or
biological product, whereas a complementary diagnostic
assay is a test that evaluates a biomarker for the compan-
ion product to assess the risk/benefit ratio for a subset of
patients [84, 85]. A complementary assay is not deemed
essential in decision-making for the companion product.
Avelumab was approved without a companion/comple-
mentary assay (Table 2).
Evaluation of PD expression on tumor cells and
tumor-infiltrating T cells assists clinical decisions [86–88].
A variety of detection platforms were studied at different
levels (protein, mRNA). Four immunohistochemistry (IHC)-
based assays have been approved by FDA (Table 2). These
assays include Dako 22C3, 28-8, and Ventana SP142 and
SP263 [89, 90]. These bioassays have disparate positivity cut-
off points and scoring systems in different tissue types.
Therefore, standardization of clinical decision-making
proves to be highly challenging.
Multiple studies have suggested that PD-L1 expression
is affected by the specimen size, biopsy location, variable
components of tumor and immune microenvironment,
and tumor transformation [89]. To use PD-L1 as a pre-
dictive biomarker in clinical practice, these factors
should be taken into consideration.
There exists a soluble form of PD-L1 (sPD-L1) in the
sera of patients [91–94]. It remains unclear whether
sPD-L1 level has correlation with clinical response to
the checkpoint inhibitor treatment. It has been
suggested that high sPD-L1 levels correlate with poor
prognosis [95–98]. Liquid biopsy is increasingly used as
a substitute of tissue sampling [99]. The value of liquid
biopsy results and correlation with response to PD anti-
bodies are uncertain at this time. Further development
of multi-parameter biomarker panels is urgently needed.
Conclusion and future directions
PD antibodies are revolutionizing cancer immunother-
apy. The clinical use of PD antibodies is rapidly expand-
ing. It has been shown that treatment history with
hypomethylating agents appears to enhance response to
PD-1 antibody [45]. Recent reports have shown that
pembrolizumab is able to enhance CAR-T cell activity
[100, 101]. Incorporation of PD antibodies into chemo-
therapy regimens is in active clinical investigations.
Combination of PD antibodies with small molecule
inhibitors such as IDO inhibitors and TKIs may further
increase clinical efficacy.
Abbreviations
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